AstraZeneca Holds Talks with Bristol Myers Squibb on Potential Megadeal, FT Reports
The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly $400 billion, FT said.
- On Sunday, the Financial Times reported that AstraZeneca is exploring a merger with Bristol Myers Squibb in a deal that could value the combined pharmaceutical group at nearly $400 billion.
- AstraZeneca, valued at about $264 billion, could gain a foothold by acquiring Bristol Myers Squibb, which holds a $133 billion market capitalization. The merger would create one of the world's largest pharmaceutical groups.
- Bristol Myers faces patent protection losses for Eliquis and Opdivo, which account for half of sales. However, the company reported quarterly sales of $13 billion last week, its highest ever.
- Sources suggest the companies have held talks in recent months, though the deal could materialise soon, be delayed, or fall apart. This report surfaces about a dozen years after AstraZeneca fended off a takeover attempt by Pfizer.
- Bristol Myers has aggressively expanded its portfolio, purchasing seven companies since 2007. Its strategy now focuses on newer products like Breyanzi, Opdualag, and Camzyos to sustain growth amid shifting industry landscapes.
97 Articles
97 Articles
AstraZeneca could be Britain’s next loss
AstraZeneca’s deal talks with US-headquartered Bristol Myers Squibb, which Semafor confirms remain active, would strike another blow to the UK’s effort to keep hold of its corporate champions.A merger would tilt AstraZeneca’s revenues even further away from the UK and Europe and could portend a full relisting in New York, where the company — the second- or third-biggest member of the FTSE 100, depending on the day — elevated its secondary listin…
AstraZeneca, Bristol Myers Squibb Hold Preliminary USD 400 Billion Merger Talks: Report
New York: AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions about a possible combination that would create one of the world's biggest pharmaceutical companies with a combined value...
The proposed merger of the British pharmaceutical giant is a devastating charge against British indifference.
AstraZeneca investors balk at Bristol Myers deal prospect
AstraZeneca investors punished the pharmaceutical firm yesterday over reports of merger talks with US rival Bristol Myers Squibb that could make one of the world's biggest drugmakers with a combined value of nearly $400 billion.
Coverage Details
Bias Distribution
- 45% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
